Tibolone for prevention and treatment of postmenopausal osteoporosis

被引:12
作者
Ettinger, Bruce
机构
[1] San Francisco, CA 94111
关键词
tibolone; dosage; osteoporosis; fracture; bone mineral density; prevention; treatment;
D O I
10.1016/j.maturitas.2007.02.008
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Tibolone has been widely accepted as remedy for vasomotor symptoms and for prevention of bone loss. Studies over the past 25 years have documented its effects on bone mineral density in younger and older women. Tibolone reduces bone turnover substantially (about the same amount as hormone therapy). Increases in bone mineral density (BMD) accompany this reduction in bone turnover, but like all other antiresorptive therapies, reduction in fracture risk (i.e. 50%) is always greater than would be predicted from BMD change. Finally, as with hormone therapies, dosage reductions have been prompted by new evidence of low dosage efficacy and concern over close-related side effects. Solid evidence has now emerged from large, dose-ranging studies that the 1.25 mg tibolone dosage is adequate for preservation of BMD and for reduction of fracture risk. Now that fracture efficacy has been added to the list of tibolone's documented bone benefits, physicians must consider this in the overall risks and benefits of its use. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:35 / 38
页数:4
相关论文
共 50 条
[41]   Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis [J].
Ellerington, MC ;
Hillard, TC ;
Whitcroft, SIJ ;
Marsh, MS ;
Lees, B ;
Banks, LM ;
Whitehead, MI ;
Stevenson, JC .
CALCIFIED TISSUE INTERNATIONAL, 1996, 59 (01) :6-11
[42]   Combination and sequential treatment in women with postmenopausal osteoporosis [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Yavropoulou, Maria P. ;
Makras, Polyzois .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (04) :477-490
[43]   Factors related with osteoporosis treatment in postmenopausal women [J].
Montagner Rossi, Lia Mara ;
Copes, Rafaela Martinez ;
Dal Osto, Leo Canterle ;
Flores, Clovis ;
Comim, Fabio Vasconcellos ;
Premaor, Melissa Orlandin .
MEDICINE, 2018, 97 (28)
[44]   Osteoporosis: Increasing Screening and Treatment for Postmenopausal Women [J].
French, Karen D. ;
Emanuele, Donna .
JNP-JOURNAL FOR NURSE PRACTITIONERS, 2019, 15 (05) :347-350
[45]   Strategies for the prevention and treatment of osteoporosis during early postmenopause [J].
Delaney, MF .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 194 (02) :S12-S23
[46]   Treatment of postmenopausal osteoporosis with odanacatib [J].
Chapurlat, Roland D. .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) :559-564
[47]   Postmenopausal Osteoporosis: A Clinical Review [J].
Watts, Nelson B. .
JOURNAL OF WOMENS HEALTH, 2018, 27 (09) :1093-1096
[48]   Effects of Tibolone on Bone Mass in Postmenopausal Women [J].
Krejovic, Snezana Maric ;
Zivanovic, Aleksandar ;
Hasani, Bajram ;
Ille, Tatjana ;
Glisic, Andrea .
TURKISH JOURNAL OF RHEUMATOLOGY, 2011, 26 (03) :226-232
[49]   Prevention and treatment of osteoporosis in postmenopausal women - Defining the role of alendronate [J].
Keam, SJ ;
Plosker, GL .
DISEASE MANAGEMENT & HEALTH OUTCOMES, 2004, 12 (01) :19-37
[50]   Prevention and treatment of postmenopausal osteoporosis The role of hormone replacement therapy [J].
Thomasius, Friederike ;
Hadji, Peyman .
GYNAKOLOGE, 2020, 53 (01) :19-24